Prostate Cancer Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Table of Contents
1  RESEARCH SCOPE
    1.1 Research Product Definition
    1.2 Research Segmentation
        1.2.1 Product Type
        1.2.2 Main product Type of Major Players
    1.3 Demand Overview
    1.4 Research Methodology
2 GLOBAL PROSTATE CANCER DRUGS INDUSTRY
    2.1 Summary about Prostate Cancer Drugs Industry
    2.2 Prostate Cancer Drugs Market Trends
        2.2.1 Prostate Cancer Drugs Production & Consumption Trends
        2.2.2 Prostate Cancer Drugs Demand Structure Trends
    2.3 Prostate Cancer Drugs Cost & Price
3  MARKET DYNAMICS
    3.1 Manufacturing & Purchasing Behavior in 2020
    3.2 Market Development under the Impact of COVID-19
        3.2.1 Drivers
        3.2.2 Restraints
        3.2.3 Opportunity
        3.2.4 Risk
4  GLOBAL MARKET SEGMENTATION
    4.1 Region Segmentation (2017 to 2021f)
        4.1.1 North America (U.S., Canada and Mexico)
        4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
        4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
        4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
        4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
    4.2 Product Type Segmentation (2017 to 2021f)
        4.2.1 Hormonal Therapy
        4.2.2 Chemotherapy
        4.2.3 Immunotherapy
        4.2.4 Targeted Therapy
    4.3 Consumption Segmentation (2017 to 2021f)
        4.3.1 Clinics
        4.3.2 Hospitals
        4.3.3 Other
5  NORTH AMERICA MARKET SEGMENT
    5.1 Region Segmentation (2017 to 2021f)
        5.1.1 U.S.
        5.1.2 Canada
        5.1.3 Mexico
    5.2 Product Type Segmentation (2017 to 2021f)
        5.2.1 Hormonal Therapy
        5.2.2 Chemotherapy
        5.2.3 Immunotherapy
        5.2.4 Targeted Therapy
    5.3 Consumption Segmentation (2017 to 2021f)
        5.3.1 Clinics
        5.3.2 Hospitals
        5.3.3 Other
    5.4 Impact of COVID-19 in North America
6  EUROPE MARKET SEGMENTATION
    6.1 Region Segmentation (2017 to 2021f)
        6.1.1 Germany
        6.1.2 UK
        6.1.3 France
        6.1.4 Italy
        6.1.5 Rest of Europe
    6.2 Product Type Segmentation (2017 to 2021f)
        6.2.1 Hormonal Therapy
        6.2.2 Chemotherapy
        6.2.3 Immunotherapy
        6.2.4 Targeted Therapy
    6.3 Consumption Segmentation (2017 to 2021f)
        6.3.1 Clinics
        6.3.2 Hospitals
        6.3.3 Other
    6.4  Impact of COVID-19 in Europe
7  ASIA-PACIFIC MARKET SEGMENTATION
    7.1 Region Segmentation (2017 to 2021f)
        7.1.1 China
        7.1.2 India
        7.1.3 Japan
        7.1.4 South Korea
        7.1.5 Southeast Asia
        7.1.6 Australia
        7.1.7 Rest of Asia Pacific
    7.2 Product Type Segmentation (2017 to 2021f)
        7.2.1 Hormonal Therapy
        7.2.2 Chemotherapy
        7.2.3 Immunotherapy
        7.2.4 Targeted Therapy
    7.3 Consumption Segmentation (2017 to 2021f)
        7.3.1 Clinics
        7.3.2 Hospitals
        7.3.3 Other
    7.4  Impact of COVID-19 in Europe
8  SOUTH AMERICA MARKET SEGMENTATION
    8.1 Region Segmentation (2017 to 2021f)
        8.1.1 Brazil
        8.1.2 Argentina
        8.1.3 Rest of Latin America
    8.2 Product Type Segmentation (2017 to 2021f)
        8.2.1 Hormonal Therapy
        8.2.2 Chemotherapy
        8.2.3 Immunotherapy
        8.2.4 Targeted Therapy
    8.3 Consumption Segmentation (2017 to 2021f)
        8.3.1 Clinics
        8.3.2 Hospitals
        8.3.3 Other
    8.4  Impact of COVID-19 in Europe
9  MIDDLE EAST AND AFRICA MARKET SEGMENTATION
    9.1 Region Segmentation (2017 to 2021f)
        9.1.1 GCC
        9.1.2 North Africa
        9.1.3 South Africa
        9.1.4 Rest of Middle East and Africa
    9.2 Product Type Segmentation (2017 to 2021f)
        9.2.1 Hormonal Therapy
        9.2.2 Chemotherapy
        9.2.3 Immunotherapy
        9.2.4 Targeted Therapy
    9.3 Consumption Segmentation (2017 to 2021f)
        9.3.1 Clinics
        9.3.2 Hospitals
        9.3.3 Other
    9.4  Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
    10.1 Brief Introduction of Major Players
        10.1.1 AbbVie
        10.1.2 Astellas Pharma
        10.1.3 Astra Zeneca
        10.1.4 Johnson & Johnson
        10.1.5 Sanofi
        10.1.6 GlaxoSmithKline
        10.1.7 Merck Group
        10.1.8 Novartis
        10.1.9 Amgen
        10.1.10 Bayer HealthCare
        10.1.11 Ferring Pharmaceutical
        10.1.12 Janssen Pharmaceuticals
        10.1.13 Endo Pharmaceuticals
        10.1.14 BMS
        10.1.15 Takeda Pharmaceuticals
        10.1.16 Northwest Biotherapeutics
        10.1.17 Teva Pharmaceutical
        10.1.18 Boehringer Ingelheim
        10.1.19 Foresee Pharmaceuticals
        10.1.20 Tokai Pharmaceuticals
        10.1.21 Spectrum Pharmaceuticals
    10.2  Prostate Cancer Drugs Sales Date of Major Players (2017-2020e)
        10.2.1 AbbVie
        10.2.2 Astellas Pharma
        10.2.3 Astra Zeneca
        10.2.4 Johnson & Johnson
        10.2.5 Sanofi
        10.2.6 GlaxoSmithKline
        10.2.7 Merck Group
        10.2.8 Novartis
        10.2.9 Amgen
        10.2.10 Bayer HealthCare
        10.2.11 Ferring Pharmaceutical
        10.2.12 Janssen Pharmaceuticals
        10.2.13 Endo Pharmaceuticals
        10.2.14 BMS
        10.2.15 Takeda Pharmaceuticals
        10.2.16 Northwest Biotherapeutics
        10.2.17 Teva Pharmaceutical
        10.2.18 Boehringer Ingelheim
        10.2.19 Foresee Pharmaceuticals
        10.2.20 Tokai Pharmaceuticals
        10.2.21 Spectrum Pharmaceuticals
    10.3  Market Distribution of Major Players
    10.4 Global Competition Segmentation
11  MARKET FORECAST
    11.1  Forecast by Region
    11.2  Forecast by Demand
    11.3  Environment Forecast
        11.3.1  Impact of COVID-19
        11.3.2  Geopolitics Overview
        11.3.3  Economic Overview of Major Countries
12  REPORT SUMMARY STATEMENT